文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

NKG2D-based chimeric antigen receptor therapy induced remission in a relapsed/refractory acute myeloid leukemia patient.

作者信息

Sallman David A, Brayer Jason, Sagatys Elizabeth M, Lonez Caroline, Breman Eytan, Agaugué Sophie, Verma Bikash, Gilham David E, Lehmann Frédéric F, Davila Marco L

机构信息

Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA

Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.

出版信息

Haematologica. 2018 Sep;103(9):e424-e426. doi: 10.3324/haematol.2017.186742. Epub 2018 Apr 27.

DOI:10.3324/haematol.2017.186742
PMID:29703727
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6119132/
Abstract
摘要

相似文献

[1]
NKG2D-based chimeric antigen receptor therapy induced remission in a relapsed/refractory acute myeloid leukemia patient.

Haematologica. 2018-9

[2]
Chimeric Antigen Receptor T Cells Targeting NKG2D-Ligands Show Robust Efficacy Against Acute Myeloid Leukemia and T-Cell Acute Lymphoblastic Leukemia.

Front Immunol. 2020

[3]
Adoptive cell therapy for acute myeloid leukemia.

Leuk Lymphoma. 2019-1-10

[4]
NK Cells Expressing a Chimeric Activating Receptor Eliminate MDSCs and Rescue Impaired CAR-T Cell Activity against Solid Tumors.

Cancer Immunol Res. 2019-1-16

[5]
[NKG2D CAR-T cells as an immunotherapy in hepatocellular carcinoma].

Med Sci (Paris). 2020

[6]
Anti-CD19 chimeric antigen receptors T cells for the treatment of relapsed or refractory E2A-PBX1 positive acute lymphoblastic leukemia: report of three cases.

Leuk Lymphoma. 2019-2-4

[7]
Allogeneic FLT3 CAR T Cells with an Off-Switch Exhibit Potent Activity against AML and Can Be Depleted to Expedite Bone Marrow Recovery.

Mol Ther. 2020-10-7

[8]
Cellular immunotherapy for acute myeloid leukemia: How specific should it be?

Blood Rev. 2019-2-23

[9]
Manufacturing development and clinical production of NKG2D chimeric antigen receptor-expressing T cells for autologous adoptive cell therapy.

Cytotherapy. 2018-6-29

[10]
Anti-human CD117 CAR T-cells efficiently eliminate healthy and malignant CD117-expressing hematopoietic cells.

Leukemia. 2020-5-1

引用本文的文献

[1]
CAR-T cell therapy in AML: recent progress and future perspectives.

Int J Hematol. 2024-10

[2]
Chimeric antigen receptor T-cell therapy in childhood acute myeloid leukemia: how far are we from a clinical application?

Haematologica. 2024-6-1

[3]
Dual Targeting of Glioblastoma Cells with Bispecific Killer Cell Engagers Directed to EGFR and ErbB2 (HER2) Facilitates Effective Elimination by NKG2D-CAR-Engineered NK Cells.

Cells. 2024-1-28

[4]
Cancer Nano-Immunotherapy: The Novel and Promising Weapon to Fight Cancer.

Int J Mol Sci. 2024-1-18

[5]
Chimeric Antigen Receptor T Cell Therapy in Acute Myeloid Leukemia: Trials and Tribulations.

Hematol Rep. 2023-11-12

[6]
NKG2D-CAR memory T cells target pediatric T-cell acute lymphoblastic leukemia and but fail to eliminate leukemia initiating cells.

Front Immunol. 2023

[7]
Unveiling T cell evasion mechanisms to immune checkpoint inhibitors in acute myeloid leukemia.

Cancer Drug Resist. 2023-9-26

[8]
Targeting NKG2DL with Bispecific NKG2D-CD16 and NKG2D-CD3 Fusion Proteins on Triple-Negative Breast Cancer.

Int J Mol Sci. 2023-8-24

[9]
Chimeric antigen receptor-natural killer cells: a promising sword against insidious tumor cells.

Hum Cell. 2023-11

[10]
NK cell defects: implication in acute myeloid leukemia.

Front Immunol. 2023

本文引用的文献

[1]
Study protocol for THINK: a multinational open-label phase I study to assess the safety and clinical activity of multiple administrations of NKR-2 in patients with different metastatic tumour types.

BMJ Open. 2017-11-12

[2]
Chimeric antigen receptors for adoptive T cell therapy in acute myeloid leukemia.

J Hematol Oncol. 2017-8-29

[3]
Exploiting natural killer group 2D receptors for CAR T-cell therapy.

Future Oncol. 2017-6-14

[4]
Toxicities of chimeric antigen receptor T cells: recognition and management.

Blood. 2016-6-30

[5]
IDH mutant gliomas escape natural killer cell immune surveillance by downregulation of NKG2D ligand expression.

Neuro Oncol. 2016-10

[6]
T cells expressing CD123 chimeric antigen receptors for treatment of acute myeloid leukemia.

Curr Opin Hematol. 2015-11

[7]
Chimeric antigen receptor T cells for sustained remissions in leukemia.

N Engl J Med. 2014-10-16

[8]
Treatment of CD33-directed chimeric antigen receptor-modified T cells in one patient with relapsed and refractory acute myeloid leukemia.

Mol Ther. 2015-1

[9]
NKG2D CARs as cell therapy for cancer.

Cancer J. 2014

[10]
Advances in NKG2D ligand recognition and responses by NK cells.

Immunol Cell Biol. 2014-1-21

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索